| Theme | Antiplatelet and Anticoagulation Therapy in Patients with Chronic Kidney Disease -- up to date of evidence | |
|---|---|---|
| Title | Antiphospholipid syndrome | |
| Publish Date | 2012/07 | |
| Author | Hideki Kasahara | Department of Rheumatology, Sapporo Medical Center NTT East |
| Author | Takao Koike | Department of Rheumatology, Sapporo Medical Center NTT East |
| [ Summary ] | Antiphospholipid syndrome is an acquired autoimmune disorder defined by the presence of antiphospholipid antibodies and the occurrence of at least one associated clinical condition including venous, arterial, and small-vessel thrombosis, habitual abortion and preterm delivery. Antiphospholipid antibodies detected in antiphospholipid syndrome have been thought to have a direct prothrombotic effect in vivo. However, the pathophysiology underlying their coagulopathic effect has not been defined. Emerging data suggest that antiphospholipid antibodies promote activation of endothelial cells, monocytes and platelets. Overproduction of tissue factors and thromboxan A2 may also be causitive factors. Complement activation may also play a central pathogenic role. State of the art advances in treatment of antiphospholipid syndrome are illustrated. |
|